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Introduction
Prostate cancer is the most commonly diagnosed non-
cutaneous malignancy in men and remains the second-
leading cause of cancer-related death in men (1,2). Despite 
advances in screening for and early detection of prostate 
cancer, a large portion of men continue to present with 
advanced or metastatic disease-approximately 20% of men 
in recent reports (3). Indeed, the morbidity from this disease 
remains high, with more than 29,000 prostate cancer related 
deaths in 2013 alone (1).
Androgen deprivation therapy (ADT), the standard of 
care for patients with biochemical recurrence after definitive 
primary therapy, locally advanced disease or metastatic 
disease, has been demonstrated to provide an initial benefit, 
but the majority of patients will progress to castration-
resistant disease within 2-3 years (4).
Castration-resistant prostate cancer (CRPC), previously 
called hormone-refractory prostate cancer, is now 
understood to be a progression of disease despite medical 
or surgical castration. The paradigm shift is due to the 
understanding that CRPC is not hormone-refractory—
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in fact, the androgen axis continues to play an important 
role in the function and growth of CRPC. Indeed, while 
other pathways can contribute to castration-resistance, the 
androgen receptor (AR) remains the most important driver 
in the continuum of CRPC. 
Understanding the mechanisms of resistance that cause 
hormone-naive prostate cancer to progress to castration-
resistance is the key to developing future therapy. In this 
review, we will review the current knowledge regarding 
the mechanisms leading to castration resistance, the 
agents currently available for treatment of CRPC, and the 
mechanisms of resistance against these agents.
Background
Understanding the androgen axis is a key component 
to understanding the mechanisms by which castration-
resistance develops. 
Androgen receptor (AR)
The AR gene on Xq11-12 encodes for a 110 kDa nuclear 
receptor with four distinct functional motifs—the amino-
terminal domain (NTD), DNA-binding domain, hinge 
region, and ligand-binding domain (LBD) (5-7). The 
cytoplasmic receptor is bound by heat-shock proteins 
(specifically HSP90 chaperone complex) in the inactive 
state (8). Androgen binding, specifically dihydrotestosterone 
(DHT) or testosterone, to the LBD causes a conformational 
change that leads to dissociation of the HSP90 complex, 
homo-dimerization of the receptor, translocation to the 
nucleus, and binding to androgen-response elements (AREs) 
in the promoter region of androgen-regulated genes (6,9). 
This interaction with the promoter region is under the 
influence of many transcriptional coregulators. Over 150 
proteins have been identified (10), and many are enzymes 
(histone acetyltransferases, methyltransferases, kinases) that 
act to open the chromatin structure to promote transcription.
Androgens
Prostate cancer growth and survival depends on androgens, 
the major ligands for the AR. Testosterone is the primary 
circulating androgen, with approximately 90% produced 
by Leydig cells in the testes and 10% produced by the 
adrenal cortex. Only a small portion (3%) of circulating 
testosterone is unbound and functionally active—the 
remainder is bound and sequestered by sex-hormone 
binding globulin and albumin. However, testosterone is not 
the primary functionally active androgen in the prostate 
microenvironment. Following diffusion into the cytoplasm, 
testosterone is converted by the enzyme 5α-reductase to 
DHT, which has a five-fold higher affinity for the LBD of 
AR (11-13).
Physiologic levels of androgens are required to promote 
growth and prevent apoptotic death. Therefore, the 
pathways under AR influence are varied, but focus on 
the functions of the luminal epithelial cells, including 
production of seminal fluid proteins such as prostate-
specific antigen (PSA) and multiple genes in the metabolic 
pathway leading to increased protein and lipid synthesis 
(14-16).
Steroidogenesis, which leads to androgen production, is an 
important pathway to understand, as it can be fundamentally 
altered in CRPC. Testosterone is produced by the testes 
and adrenal gland, and then converted in the cytoplasm 
to DHT via the activity of 5α-reductase (17). However, in 
the presence of ADT, studies have demonstrated persistent 
levels of intratumoral DHT (18-21), suggesting that altered 
steroidogenesis pathways have been activated (20). Adrenal 
testosterone sources, unaffected by ADT, and intratumoral 
de novo androgen synthesis may be sources of persistent 
ligand-dependent AR activity in CRPC (22). 
Androgen deprivation therapy (ADT)
Since Huggins and Hodges (23) first demonstrated the 
dependence of prostate cancer on androgen signaling, ADT 
through either medical or surgical castration has been the 
standard of care for metastatic and locally advanced disease. 
Surgical castration, or bilateral orchiectomy, removes 
testicular androgens from circulation by removal of the 
source. Medical castration is achieved through the use of 
different classes of agents. LHRH agonists and antagonists 
deplete the pituitary production of luteinizing hormone 
(LH) through negative feedback or competitive inhibition, 
respectively, which in turn prevents testicular testosterone 
production (24). Anti-androgens work as competitive 
inhibitors at the LBD of AR, thereby preventing androgen 
stimulation of AR. These agents, in conjunction, provide 
complete androgen blockade (25,26).
Castration resistance
Despite the initial response to androgen blockade, all 
patients will eventually progress to castration resistance. 
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Castration resistance is progression of disease, either 
clinical (development of metastatic disease, progression of 
pre-existing disease) or biochemical (three consecutive rises 
in PSA levels above nadir) in the presence of castrate levels 
of circulating testosterone (<50 ng/dL) (27,28).
Indeed, the biochemical recurrence of PSA, an AR 
regulated gene measured by serum levels, is evidence 
that CRPC is not hormone-insensitive. When adding 
first generation anti-androgens, such as flutamide or 
bicalutamide, to the treatment regimen of patients with 
advanced or metastatic disease, a decrease in serum PSA 
is often initially noted, indicating a response to direct AR 
blockage (29,30). However, serum PSA levels will again rise 
despite anti-androgen therapy, suggesting that the agent has 
begun functioning as an AR agonist; this is validated by the 
PSA decrease noted with anti-androgen withdrawal (31,32).
Further evidence for the critical role of the androgen axis 
in the development of CRPC lies in the finding that, despite 
castrate levels of serum testosterone, there remains a higher 
level of intra-tumoral androgens in CRPC compared to 
hormone-naïve prostate cancer (18-21). Recent studies have 
demonstrated that intra-tumoral androgen levels in CRPC 
are similar to those of eugonadal men, and in some cases 
even increased (22,33).
The AR persists in CRPC cells, and the re-activation 
of this axis by the following mechanisms appears to drive 
progression to castration-resistance. 
AR dependent mechanisms of resistance 
leading to CRPC
The majority of mechanisms identified leading to 
castration-resistant are mediated by AR or the androgen 
axis. As seen in Figure 1, they can be categorized into five 
main subsets.
AR amplification and mutations/hypersensitivity pathway/
promiscuous pathway
Low levels of androgen persist despite androgen blockade 
with ADT. Within this microenvironment, a subset of cells 
develop sensitivity to these low levels of androgens either 
through amplification of the AR (hypersensitivity pathway) (34) 
or development of AR mutations that lead to activation by 
molecules other than androgens (promiscuous pathway) (35,36). 
Amplification of the AR has been identified in a 
significant portion of CRPC cell lines, ranging from 30-
80% (37,38). This finding is uncommon in hormone naïve 
prostate cancer and may be due to selective outgrowth of 
CRPC cells (36). This amplification enables CRPC to be 
hypersensitive to low level of androgens, which promotes 
progression of disease (35). As 20% of CRPC metastases 
have evidence of AR amplification, which is absent in 
hormone-naive metastatic disease, it may also contribute 
to metastases. In addition, recent studies have shown that 
exogenous overexpression of AR can lead to CRPC. 
Related to this concept, a substitution of valine with 
leucine at codon 89 results in increased 5α-reductase levels 
in a subset of CRPC. This results in higher levels of DHT 
despite low circulating levels of testosterone. This mutation 
is more commonly observed in the African-American 
population, and has been associated with more aggressive, 
early onset prostate cancer (39,40).
There have been various point mutations identified 
in the AR gene itself that lead to increased AR activity in 
the presence of low levels of androgens as well as non-
androgenic steroids, such as progesterone, hydrocortisone, 
estradiol, and certain AR antagonists. The substitution of 
threonine with alanine at codon 877 in LNCAP cells (41,42) 
and the substitution of histidine for tyrosine in CWR22 cells 
(43,44) are well described in the literature; other examples 
include L701H, V715M, W741C (45-47). While most of the 
mutations are predominantly in the LBD, mutations in the 
NTD and DNA-binding domain were also identified (48,49). 
Co-activators and co-repressors
Over 150 different molecules have already been identified as 
co-activators and co-repressors for AR (10). The AR normally 
recruits a series of coregulator complexes, which can function 
to either enhance (co-activators) or repress (co-repressors) 
transcriptional activity. Many of these coregulators are 
enzymes that serve to modulate other proteins in the complex, 
either through phosphorylation, methylation, acetylation or 
ubiquitylation, but they have also been identified as molecular 
chaperones, recruiters of transcriptional machinery and RNA 
splicing regulators (50-52). 
One coactivator, FKBP51, which is also an AR target 
gene, was found to be upregulated in relapsed LAPC-4 
tumors grown in castrate mice (53). It promotes formation of 
a superchaperone complex by regulating the recruitment of 
p23, a co-chaperone, to ATP-bound Hsp90, which in turns 
keeps AR in a conformation with high-affinity for ligand 
binding. This promotes androgen-stimulated transcriptional 
activity and growth. 
The steroid receptor coactivators (SRC) are a class of 
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AR coactivators capable of acetyltransferase activity, which 
in turn enhances AR-induced transcription by promoting 
formation of complexes between AR-associated enhancers/
promoters and the transcription start site of AR target 
genes (54). The SRC class includes SRC-1, SRC-2 (TIF-2, 
GRIP-1, NcoA2), and SRC-3 (AIB). Xu et al. demonstrated 
that all three have been associated with prostate cancer 
progression (55). Ueda et al. identified SRC-1, when 
phosphorylated by MAPK under the influence of IL-6, was 
capable of both ligand-dependent and ligand-independent 
AR activation (56). SRC-3, in particular, tends to be over 
amplified in human cancers. Chung et al. demonstrated that 
SRC-3 is not overexpressed in androgen-dependent prostate 
cancer, but is overexpressed in poorly differentiated and 
more advanced prostate cancer, and is directly associated with 
prostate cancer progression—SRC-3 knockout mice were 
effectively arrested at the well-differentiated stage and unable 
to progress to poorer pathology (57). 
Other important pathways include p300/CBP, which 
promotes androgen-independent IL-6 mediated AR activation 
in the presence of STAT3 (58), and LSD1 and JMJD2c, lysine 
demethylases that demethylate the histone H3 proteins and 
lead to increased AR induced transcription (59). Many of 
these molecules have demonstrated AR-dependent and AR-
independent effects, since their interaction is not limited to 
AR. Co-repressor proteins, on the other hand, have been 
found at reduced levels in CRPC. 
Aberrant activation (post-translational modification)/
outlaw pathway
While all the prior mechanisms mediate increased AR activity 
Figure 1 Androgen receptor-dependent mechanisms of resistance in hormone-naive prostate cancer leading to castration-resistance. 
wtAR, wild-type androgen receptor; ARV, androgen receptor variant; mutAR, mutated androgen receptor; T, testosterone; DHT, 
dihydrotestosterone; SHGB, sex hormone binding globulin.
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in the presence of ligand, ligand-independent AR activation 
is also an important mechanism of progression to castration-
resistance. Various in vitro studies have suggested that multiple 
growth factors, cytokines, and kinase pathways increase 
AR signaling, thereby promoting progression to castration 
resistance in a ligand-independent manner (60). Identification 
and characterization of those ligand-independent pathways 
can lead to additional targeted therapies.
The NF-κB family of proteins has been established as an 
important component of the oncogenic pathway in multiple 
human malignancies. There are five distinct NF-κB 
proteins, including the well-studied p65/p50 heterodimer, 
which has been shown to be constitutively active in prostate 
cancer. Another of the NF-κB pathways, the p100/p52 
pathway has been of recent interest. The processing of 
p100 to p52 via molecules such as lymphotoxin β, B-cell 
activating factor, CD40 ligand, and stat3 (61) in prostate 
cancer, leads to significant hyperplasia and induced 
castration-resistant growth. This was accomplished by 
limiting ADT mediated apoptosis and cell cycle inhibition, 
but was done so in the presence of continued AR expression 
and activation, which suggested that p52 may activate AR 
during the progression of CRPC. p52 mediated its effects 
in an AR dependent manner by interacting directly with the 
NTD of AR. Downregulation of p52 in C4-2 cells led to 
the loss of constitutive activation of AR which suggested an 
androgen independent activation of AR (62). 
The PI3K pathway is another important player in this 
process. The loss of the tumor suppressor PTEN protein, 
which is a negative inhibitor of the PI3K/AKT pathway, 
is identified in nearly all metastatic prostate cancers. Its 
activation has been associated with development of CPRC 
in various preclinical models (63-65). PI3K, specifically the 
p110β isoform, has been strongly associated with prostate 
cancer growth and progression, through basal activation of 
AKT in prostate cancer models. The PI3K/AKT pathway is 
downstream of key receptor tyrosine kinases (RTKs) such as 
EGFR, IGFR, c-met, but some studies suggest independent 
activation of this pathway (66). While it is also upstream of 
some critical signaling proteins, such as mTOR, it has also 
been found that AKT directly phosphorylates AR at two 
locations, Ser-217 and Ser-791, particularly in a castrate-
state, though the clinical significance is not yet certain (67). 
Src kinase, the key member in the family of non-RTK 
called Src family of kinases (SFK), has been a focus of our lab 
and our collaborators. Src, in the 25 years since its discovery 
as the first proto-oncogene identified, has been targeted in 
the treatment of multiple other malignancies (68,69). Our 
research into the role of Src in prostate cancer identified 
Src as a key molecule in multiple pathways that allow for 
progression of prostate cancer (70,71). Src is expressed 
in commonly used CaP cell lines CWR22Rv1, DU145, 
LAPC-4, LNCaP, and PC-3. As Src is not constitutively 
active, it has been difficult correlating Src protein expression 
levels with cell proliferation or aggressiveness in vitro. 
However, Src kinase is downstream of many important 
prostate-cancer influences—as it is activated by growth 
factors, cytokines, chemokines, and gastrin-releasing 
peptide, it has a pleiotropic effect on prostate cancer 
(68,70,71). Our laboratory group demonstrated that higher 
relative Src activation was associated with worse prostate 
cancer phenotypes, specifically DU145 and PC3, and the 
use of a novel SRC inhibitor AZD0530 helped elucidate a 
few of the pathways mediated by Src in prostate cancer cell 
lines (70). Activation of Src kinase has been linked to 
androgen-independent cell growth (72-74), inhibition 
of anti-apoptotic pathways (75-77), cell migration and 
adhesion (73), and tumor invasion (78), among other aspects 
of prostate cancer cell biology. Based on this preclinical data, 
AZD0530 (saracatinib) was taken to phase II clinical trial, 
but it was demonstrated to have minimal clinical efficacy as 
monotherapy (79). Lack of clinical efficacy was also noted 
with dasatinib; in the phase III clinical trial of docetaxel 
with dasatinib or placebo in chemotherapy-naïve CRPC 
patients, there was no improvement in overall survival (80). 
Other non-tyrosine kinases, such as Btk and Etk within 
the Tek-family of non-tyrosine kinases, are being targeted 
as well; recent work by Guo and colleagues demonstrated 
that CTN06, a novel dual inhibitor of Btk and Etk, induced 
apoptosis and autophagy, and also re-sensitized cell lines to 
docetaxel (81). 
Growth factor pathways, such as IGF and KGF, bind and 
activate AR in a castrate state. Growth factor receptors, such 
as IGF-1R, IL-6R, and EGFR, control critical downstream 
growth and survival pathways such as MAPK, PI3K/AKT, 
and STAT signaling. Various RTKs, such as Her-2/neu, 
EGFR, and IGR-1R, enhance AR stability and activity, and 
in some cases, promote androgen independence. Her2/neu, 
for example, was found to promote xenograft cell growth via 
Ack1-kinase, which phosphorylates AR at tyrosine-267 and 
activates it (82). Targeting these pathways has shown some 
promise—cabozantinib (XL-184) inhibits tyrosine kinases of 
c-Met and VEGF, and in phase II clinical trial, demonstrated 
significant benefit specifically for CRPC patients with bone 
metastases; However, it did not reach its primary endpoint 
(bone pain alleviation) in phase III trial, with no significant 
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difference in bone pain alleviation between the treatment and 
control (mitoxantrone/prednisone) arms. 
Altered steroidogenesis
CRPC develops in the presence of castrate-levels of 
circulating androgens. However, intra-tumoral levels of 
androgens in CRPC models have been established to 
be the same as or even higher than in eugonadal men, 
suggesting that there is alternative androgen production 
(18-22,33). This is likely due to adrenal production, 
specifically of androgen precursors of adrenal origin such 
as dehydroepiandrosterone (DHEA) and its sulfated form 
(DHEA-S), which can be converted to the highly active 
DHT via a “backdoor” pathway (83,84). 
DHEA and DHEA-S, produced by the adrenal gland, are 
not affected by ADT and are still found in circulation. The 
molecules are converted to androstenedione (AD) either 
in the prostate or adrenal gland by 3βHSD, encoded by 
HSD3B. There are 2 isoforms, 3βHSD1 in the prostate and 
peripheral tissues, 3βHSD2 in the adrenal gland (85). The 
subsequent conversion from AD to DHT, in the absence of 
ADT, typically goes through testosterone as an intermediary, 
and requires 17βHSD3 and AKR1C3 (encoded by HSD17B3 
and AKR1C3 respectively) and steroid-5α-reductase (two 
isoforms, encoded by SRD5A1 and SRD5A2). However, in 
the presence of ADT, the sequence can be reversed, leading 
to 5α-AD (5α-dione) serving as the intermediary between 
AD and DHT, bypassing testosterone completely. This 
alternative pathway, referred to as the “5α-dione” pathway, 
has been demonstrated to predominate in CRPC (86,87). 
In addition to utilization of weak adrenal androgens in 
the 5α-dione pathway, recent assessment of CRPC cells has 
identified increased expression of steroidogenic enzymes such 
HSD3B1, HSD3B2, HSD17B3, AKR1C3, and SRD5A1 
(20,87-89), which may contribute to de novo production 
of steroids and androgens. Up-regulation of SRD5A1 and 
concurrent down-regulation of SRD5A2 leads to higher 
levels of 5α-reductase-1, for which AD is a better substrate 
than testosterone (90-92). What drives the changes in 
transcription of these steroidogenic enzymes? Many single-
nucleotide polymorphisms have been identified within the 
above enzymes, especially HSD3B1 and HSD3B2 (93), but 
the clinical significance of these is not yet clear.
AR variants
A more recent development has been the identification of 
splice variants of the AR (AR-Vs), which are constitutively 
active, typically due to the loss of the C-terminal LBD 
(94-97). Indeed, the amplification of AR seen in CRPC 
may contribute to the development of the splice variants. 
Most CRPC cell lines demonstrate low levels of AR-V, but 
22RV1 express levels similar to full-length AR (44). 
The functional implication of these variants is not yet 
fully understood. Direct measurement of splice variants 
has been limited by the lack of variant-specific antibodies, 
leaving only secondary assessment via RNA levels. ARV7 is 
the only variant that has a suitable antibody for staining, and 
immunohistochemistry staining has established increased 
expression in CRPC (95,96). However, transcribed RNA 
levels may not be completely reflective of protein levels. 
This suggests some post-translational control that has not 
yet been fully elucidated.
However, Hörnberg et al. reported high levels of 
splice variant expression in bone metastases compared to 
hormone-naïve prostate cancer, and that it led to CRPC 
and poorer prognosis (98). This study also demonstrated 
a discrepancy between RNA levels and protein levels, 
contributing to the difficulty in determining splice variant 
significance in CRPC development and progression. 
The predominant variants are ARV1, ARV7 and 
ARV 567. Of the variants, ARV7 has been studied most 
extensively (95,96). As described above, it lacks the LBD, 
is located in the nucleus, and is constitutively active. It 
has been show to regulate both AR-regulated genes and a 
unique set of AR-independent genes (96), suggesting it has 
an overlapping but distinct role compared to full-length AR 
in prostate cancer cells (94).
A recently discovered variant, ARV8, actually lacks 
a DNA-binding domain. Therefore, it remains in the 
plasma membrane and its constitutive activity is limited 
to activation of cell signaling pathways (99). For example, 
Yang et al. demonstrated increased AR phosphorylation via 
an EGF-mediated SRC activation in the presence of this 
variant; its subsequent knockdown was associated with loss 
of this phosphorylation.
Mechanisms of resistance to current CRPC 
treatments
Based on this understanding of the development of CRPC, 
there are now approved medications for the management 
of patients who are castration-resistant. However, despite 
these new agents, all patients will eventually progress in 
their disease. Understanding the means by which prostate 
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cancer overcomes these treatment modalities will help 
identify new treatment options.
Below, we will address the primary agents currently 
available, focusing on their mechanism of action and current 
knowledge about the resistance to their function. Figure 2 
provides an overview of the current and experimental agents 
affecting the androgen axis. As can be expected, there is 
crossover in many of these mechanisms, with these shared 
pathways being potentially significant future targets. 
Docetaxel
Docetaxel is the current standard of care for patients 
who have progressed to castrate-resistant prostate cancer. 
SWOG 9916 and TAX327 demonstrated a 3-month 
survival advantage with docetaxel over mitoxantrone in 
CRPC patients (100-102), and until recently, it was the 
only approved primary therapy for CRPC. The recent 
CHAARTED trial, however, may have demonstrated 
a role for docetaxel as an initial treatment option for 
hormone-naïve prostate cancer in conjunction with ADT, 
as the combination was found to have a 17-month survival 
advantage (103).
Docetaxel is a well-known and studied chemotherapeutic 
agent used in the treatment of a variety of malignancies. 
It is an anti-mitotic chemotherapeutic agent that works by 
binding the β subunits of tubulin in microtubules, thereby 
stabilizing them and preventing the depolymerization 
required for mitosis (104-106), which induces apoptosis. In 
CRPC specifically, docetaxel leads to phosphorylation of 
Figure 2 Current and experimental agents targeting the androgen axis. wtAR, wild-type androgen receptor; ARV, androgen receptor 
variant; LBD, ligand-binding domain; NTD, n-terminal domain; T, testosterone; DHT, dihydrotestosterone; SHGB, sex hormone binding 
globulin.
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bcl-2 (B-cell lymphoma 2), which causes caspase activation 
and apoptosis in vivo and in vitro (107,108). Additionally, 
AR expression is reduced in docetaxel-treated CRPC cells 
and is thought to be due to AR nuclear localization and 
inhibition of signaling (109).
Drug-efflux in CRPC enables resistance to docetaxel. 
Multi-drug resistance proteins (MDRP) are well described 
in the literature, and include P-glycoprotein (P-gp), 
multidrug resistance protein 1 (MRP1), and breast cancer 
resistance protein (BRCP). These molecules cause active 
efflux of multiple therapeutic agents. DU145 and 22RV1 
cell lines, when made docetaxel-resistant, have been found 
to over-express P-gp (110), while CRPC lines exposed to 
docetaxel have been found to have MDR1 genetic variations 
that are more docetaxel-resistant (111). Docetaxel-resistant 
CRPC lines also upregulate the class III β-tubulin isoform, 
which allows less taxane binding. Inhibiting class III β-tubulin 
restores docetaxel sensitivity in those same cells (112,113). 
In addition, LNCAP derived docetaxel-resistant cells 
demonstrated an F270I mutation in the class I β-tubulin, 
which had stronger taxane binding at baseline (114). 
While the above mechanisms are docetaxel-specific, 
other mechanisms of resistance have been identified. 
Docetaxel resistance has been linked to apoptosis pathways, 
specifically upregulation of p53 and activation of PAR1. 
p53 is an important cell cycle regulator, often found over-
expressed in prostate cancer. LNCAP cells over-expressing 
wild type p53 are more resistant to docetaxel activity than 
DU145 and PC3 cell lines, which have reduced or no p53 
activity (115). Zhu et al. demonstrated this in docetaxel-
resistant C42B cells in vitro—cells treated with docetaxel 
had p53 phosphorylation and activation, but taxane-
resistant C42B demonstrated no phosphorylation (116). 
PAR1, through NF-κB activation, has been shown to reduce 
docetaxel-induced apoptosis (117). 
In addition to blocking docetaxel-induced apoptosis, 
docetaxel’s anti-mitotic activity itself directly initiates 
survival pathways in prostate cancer cell lines. Binding to 
the microtubules initiates pathways such as c-Jun N-terminal 
kinase (JNK), which in turns leads to activation of various 
transcription factors such as STAT-1, STAT-3, and NF-κB. 
Knockdown models of these transcription factors have 
been shown to be more sensitive to docetaxel-cytotoxicity 
(115,118). 
Over-expression of cytokines and chemokines, such as 
IL-6, IL-8, and CCL-2, and chaperone molecules, such as 
HSP27 and HSP90, have been associated with docetaxel 
resistance, but no clinically significant inhibitors of these 
pathways have yet been identified. OGX-011, a second-
generation antisense drug that inhibits the secretion 
of clusterin, a chaperone protein, was administered in 
conjunction with docetaxel in phase III trials, but did not 
meet its primary endpoint. Its activity focuses on CLU, a 
key protein that exists in two forms: nuclear CLU (nCLU) 
and secreted CLU (sCLU)—nCLU promotes docetaxel-
mediated cell death while sCLU prevents it (119,120). 
Upon initiation of chemotherapy, especially docetaxel in 
prostate cancer cells, there is a shift in the balance towards 
sCLU, thought to be attributed to STAT-1 activation 
(110,121). However, inhibition of sCLU using antisense 
oligonucleotide re-sensitizes the cells to docetaxel (121,122). 
Our lab group identified >1,600 genes that had 
altered expression in taxane-resistant C42B cells, with 
approximately 52% being upregulated. From this subset, 
we recently identified ABCB1, which belongs to the ATP-
binding cassette (ABC) transporter family, among the top 
upregulated genes in the taxane-resistant cells. ABCB1 was 
highly expressed in taxane-resistant C42B cells, but virtually 
undetectable in taxane-sensitive C42B cells. Inhibition of 
ABCB1 expression resensitized C42B cells to docetaxel, 
and this was then confirmed in the DU-145 cell line (116). 
Apigenen, a natural molecule in the flavone family identified 
by Shukla and Gupta (123), was demonstrated to help 
resensitize cells to docetaxel therapy. 
Abiraterone and androgen synthesis inhibitors
Abiraterone acetate (Zytiga) is a molecule structurally 
similar to pregnenolone that acts as an irreversible inhibitor 
of cytochrome p450, family 17, subfamily A, polypeptide 
1 (CYP17A1). CYP17A1 is a member of the cytochrome 
p450 class of enzymes that serve as a catalyst for the 
oxidation of a variety of molecules. It has two consecutive 
enzymatic functions in the steroidogenesis pathway that 
contribute to the conversion of pregnenolone to DHT. 
Loss of CYP17A1 activity causes significant loss of 
androgen production in the peripheral organs, particularly 
adrenal androgens. It has been found to be 10-30 times 
more potent than ketoconazole, which is a non-specific 
inhibitor of p450 enzymes and previously has been used 
to generate rapid androgen ablation (106). The phase III 
trial COU-AA-301 demonstrated a 3.9-month survival 
benefit of abiraterone/prednisone over placebo/prednisone 
in patients who had progressed on docetaxel therapy (124). 
The subsequent COU-AA-302 trial demonstrated benefit 
in the pre-chemotherapy space, with improved radiographic 
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progression free survival, time to initiation of chemotherapy, 
and a trend towards improved overall survival (125).
Altered steroidogenesis was discussed as one mechanism 
by which CRPC develops. While abiraterone-naive CRPC 
cell lines utilize the “5α-dione” pathway to generate intra-
tumoral DHT by bypassing testosterone, they are still 
dependent on adrenal androgens. By irreversibly inhibiting 
this critical upstream enzyme in the steroidogenesis 
pathway, abiraterone effectively causes a significant decrease 
in intra-tumoral androgen levels by preventing production 
of adrenal androgens.
However, despite its effectiveness in inhibiting the 
steroidogenesis pathway (126), abiraterone’s effect is 
incomplete. Attard et al. demonstrated that while most 
urinary androgen metabolites and serum androgens were 
suppressed, the inhibition of CYP17 led to higher levels of 
urinary metabolite 3α5α-17HP, which correlated with the 
excretion of androsterone—which is the primary metabolite 
of 5α-reducted androgens such as DHT (127). This suggests 
that the use of abiraterone may push 17-hydroxyprogesterone 
towards the “5α-dione” pathway. 
As can be expected, over-expression or mutations of 
CYP17A1 may also contribute to abiraterone resistance (128). 
Chang et al. demonstrated that the HSD3B1 (1245C) 
mutation previously mentioned as contributing to progression 
to CRPC has also been found in abiraterone-resistant 
xenograft models, though the clinical significance of this still 
needs to be elucidated (93). Mostaghel et al. demonstrated 
that abiraterone-treated cell lines responded with increased 
expression of CYP17A1, as well as increased expression of 
enzymes in the steroidogenesis pathway, including AKR1C3 
and HSD17B3 (129). 
Other androgen synthesis inhibitors are in development 
at this time, including TAK-700 (Orteronel) and VT-
464 (Viamet), both of which are more selective for the 
17, 20-lyase inhibition (130). TAK-700 is further in 
development, currently accruing for another phase III 
clinical trial, this time assessing efficacy in chemotherapy-
naive CRPC patients; the initial phase III study in patients 
who had been treated with docetaxel demonstrated an 
improvement in radiographic progression-free survival 
(HR 0.755), but it did not meet the primary endpoint of 
improvement in overall survival (HR 0.894) (130).
Enzalutamide and androgen receptor (AR) inhibitors
In response to the many AR mediated mechanisms of 
resistance found leading to development of CRPC, there 
has been development of a new generation of androgen-
receptor signaling inhibitors. The main agent in this 
class is enzalutamide (MDV-3100, ENZA, Xtandi), 
which has been demonstrated to have a multi-pronged 
approach—preventing testosterone binding to AR, AR 
nuclear translocation, AR binding to DNA, and co-
activator recruitment (106). While the AFFIRM III trial 
demonstrated a 4.8-month survival benefit over placebo in 
CRPC patients who had failed docetaxel and the PREVAIL 
trial demonstrated an overall survival and radiographic 
progression-free survival over placebo in chemotherapy-
naïve CRPC patients (131,132), not all the patients 
benefited from treatment—a subset of patients continued 
to progress, indicating that there are significant resistance 
mechanisms that need to be identified and addressed.
One mechanism by which CRPC develops resistance to 
enzalutamide, and potentially other treatment modalities, is 
the process of autophagy. Autophagy is a catabolic process 
that, besides being constitutively active at a low basal rate, 
is activated in response to stressors, allowing cells to use 
lysosomal-mediated degradation of cellular proteins and 
organelles to regenerate energy (133-135). Autophagy 
can be used by cancer cells to prolong their survival 
under harsh conditions of metabolic stress in the tumor 
microenvironment induced by various treatment modalities, 
but excessive or deregulated autophagy can push the cells 
toward autophagic cell death or type-II programmed cell 
death (136,137). Indeed, androgen deprivation has been 
shown to induce autophagy, and while the exact mechanism 
is unknown, suppression of mTOR appears to play a critical 
role (135,138). Prior studies, by our group and others, have 
established that administration of autophagy inhibitors, 
either as monotherapy or in conjunction with established 
therapies, has had effective cytotoxic result. We demonstrated 
that the use of clomipramine and metformin, both clinical 
autophagy inhibitors, significantly increased the cytotoxicity 
associated with enzalutamide in vitro and in mouse models—
the enzalutamide/clomipramine combination decreased 
tumour size by 91%, compared with a 78% decrease with 
enzalutamide/metformin (135). There are currently many 
ongoing clinical trials assessing the role of autophagy 
inhibitors as concomitant therapy (139), including a study 
at our institution that has recently been approved to assess 
metformin and enzalutamide combination therapy.
AR point mutations are also important mechanisms of 
resistance to enzalutamide, just as in the development of 
CRPC. The Phe876Leu mutation in the LBD of AR has 
been reported to make enzalutamide into an agonist of AR, 
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though the clinical relevance of this change has not been 
documented (140,141). Similar effects were noted for the 
first generation anti-androgens bicalutamide and flutamide.
Another proposed mechanism is the “glucocorticoid 
receptor take-over” pathway. Glucocorticoid receptors 
are nuclear receptors similar in structure to the AR. 
Glucocorticoids initially have a suppressive effect on 
prostate cancer, and indeed, are often given in conjunction 
with early treatments of CRPC, including chemotherapy 
and abiraterone. However, the DNA binding domain of 
the glucocorticoid receptor is very similar to the DBD of 
the AR (142,143), and the glucocorticoid receptor has been 
shown to bind to many AR regulated genes, suggesting its 
upregulation in patients treated with chemotherapy or ADT 
may contribute to enzalutamide resistance (144). 
Many of these mechanisms may also affect upcoming 
androgen-receptor inhibitors in a similar fashion. For 
example, ARN-509, another novel AR antagonist which is 
currently in the accrual phase of a multi-center phase III 
clinical trial, has been shown to be susceptible to the same 
AR F876L mutation that converts it to an agonist (145). 
Other agents currently being developed include ODM-201.
Targeting the androgen receptor (AR): the next 
step in prostate cancer therapy
As recently published in the New England Journal of 
Medicine, Antonarakis and collaborators demonstrated 
that 20-40% of circulating tumor cells in CRPC patients 
treated with abiraterone and enzalutamide have ARV7 
constitutively active (146). More importantly, however, they 
demonstrated in this prospective trial that the subset of men 
with ARV7 in circulating tumor cells had a significantly 
lower PSA response rate, shorter progression-free survival 
and overall survival compared to men without ARV7 
expression. This study, our own research (62), and studies 
by other groups (94,145-147) demonstrate that ARVs are 
an important mechanism of resistance to newer CRPC 
agents. Liu et al. demonstrated that AR-V7 was present in 
a number of prostate cancer cell lines and that it was able 
to activate the PSA promoter in LNCaP and PC3 cells in 
the absence of androgen (148). With the loss of the LBD 
on the AR as seen in ARV-7, CRPC cell lines overcome the 
loss of circulating and intratumoral androgens mediated 
by abiraterone. Loss of the LBD, and concurrent ligand-
independent binding of AR to ARE’s, is thought to be 
the underlying mechanism of resistance to enzalutamide. 
Li et al. demonstrated that knockdown of AR-V limited 
androgen-independent growth rate of CWR22Rv1 cells and 
restored responsiveness to anti-androgens (147). 
With the growing body of evidence pointing to the 
important role of ARV’s in the development of resistance 
and the concurrent finding that many of the current 
mechanisms of progression to CRPC involve alterations in 
the AR pathway, targeting the AR appears to be the next 
major step in prostate cancer therapy. 
Our lab previously identified niclosamide, used clinically 
to treat helminth infections, as an inhibitor of ARV7, by 
promoting its degradation; co-treatment with enzalutamide 
demonstrated a synergistic response (148). Similarly, we 
also established that miR-let-7c, a microRNA of the let-7 
family, antagonizes AR expression via c-myc degradation, 
leading to inhibition of prostate cancer proliferation (149). 
Others have also started to focus on the AR itself as a target 
for therapy—either reducing its expression or promoting its 
degradation. Lai et al. have identified ASC-J9, a novel AR 
degradation enhancer currently utilized clinically for other 
pathologies (150). Sadar and colleagues have been focusing 
on EPI-001, a small molecule that inhibits the N-terminal 
domain (NTD), which is present on both wild-type AR and 
AR variants (151).
Perhaps by targeting the AR and its variants, we may 
be able to overcome the deficiencies of current CRPC 
treatments.
Conclusions
Prostate cancer, especially locally advanced and metastatic 
disease, continues to be a burden on the healthcare system. 
While the prognosis is good for men diagnosed with 
localized disease, the prognosis remains poor for men with 
more advanced disease. All current therapies, from ADT to 
chemotherapy, merely slow the progression of disease, but 
all patients inevitably progress on therapy. Understanding 
the mechanisms by which these patients develop resistance 
to ADT, then subsequently to docetaxel, abiraterone, and 
enzalutamide, is important to identify future targets of 
therapy. 
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